Home LiteratureArticle Details
PMID: 18473765 Published · ppublish English Journal Article Review

Cytokines: from gut inflammation to colorectal cancer.

Current drug targets ·Vol. 9 ·No. 5 ·2008-05-00 ·Pages 375-80

Fantini MC, Pallone F

Abstract

Colorectal cancer represents a life-threatening complication of inflammatory bowel diseases. Statistics indicate that the risk to develop colorectal cancer is higher in patients affected by ulcerative colitis and to a lesser extent by Crohn's disease and that such a risk is directly proportional to the number of years of active disease. These observations suggest that chronic inflammation may substantially contribute to cancer development. However the molecular mechanisms underlying this process have been only recently started to be clarified. Indeed from the initial concept that the release of free radicals during inflammation might induce the accumulation of genetic mutations thus leading to the onset of dysplastic cells, it is now becoming clear that the large amount of cytokines and growth factors released during inflammation by immune and non immune cells may influence the carcinogenesis process. IL-6 and IL-23, cytokines which play key roles in the induction and maintenance of gut inflammation during IBDs, have been recently shown to influence the development and growth of colitis associated colorectal cancer. Moreover, the activation of the nuclear factor kappa B (NF kappa B), a transcription factor activated by several cytokines released during inflammation and responsible for many of their proinflammatory effects, have been shown to promote the growth of the colon tumors in experimental models.

MeSH Terms
Animals Cell Transformation, Neoplastic/immunology Colitis/complications,immunology,metabolism Colorectal Neoplasms/etiology,immunology,metabolism Cytokines/metabolism Humans Interleukin-23/metabolism Interleukin-6/metabolism NF-kappa B/metabolism Signal Transduction/immunology T-Lymphocytes, Helper-Inducer/immunology
Chemicals
Cytokines Interleukin-23 Interleukin-6 NF-kappa B
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Fantini Massimo C
Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy. m.fantini@med.uniroma2.it
Pallone Francesco
Article Info
Journal
Current drug targets
Abbr.
Curr Drug Targets
ISSN
1873-5592
Published
2008-05-00
Pages
375-80
Language
English
Region
United Arab Emirates
NLM ID
100960531
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com